"HDI has accomplished several critical milestones during fiscal year 2001,” said Greg H. Guettler, President. “The HDI/PulseWaveä CR-2000 Research CardioVascular Profiling System market acceptance accounted for a record setting $2,047,304 in revenue derived from pharmaceutical companies and university research centers both domestically and internationally.  Research investigators throughout the world continue to rely on the HDI/PulseWaveä CR-2000 System to deliver accurate and repeatable research data useful in assessing the impact of clinical variables on their subjects’ cardiovascular system.”  During the fiscal year 2001, worldwide pharmaceutical leader Pfizer, Inc. and the National Institutes of Health/National Heart, Lung and Blood Institute were two of the organizations that elected to incorporate the HDI/PulseWaveä CR-2000 System into their most recent clinical trials (involving thousands of subjects and over several years).

“As significant as this increase in HDI/PulseWaveä CR-2000 revenue is for HDI, the fourth quarter of fiscal year 2001 has been equally as significant,” said Guettler.   “Beginning in March of 2001, HDI began a Phase I launch of its FDA cleared CVProfilor^® DO-2020 CardioVascular Profiling System into the U.S. physician market.  All of our efforts during the fourth quarter have been directed at validating key strategic marketing assumptions through an initial, controlled launch of the CVProfilor^® into the U.S. physician and cardiovascular disease health care marketplace.  The launch of our CVProfilor^® puts HDI on a new strategic direction almost entirely devoted to U.S. physicians whose practices focus on the prevention and treatment of patients with hypertension, diabetes and other cardiovascular diseases. This new direction has also shifted our focus away from capital equipment sales of the HDI/PulseWaveä CR-2000 Research System and toward the nationwide launch of the CVProfilor^®.  Consistent with our original planned market rollout, the CVProfilor^® is being promoted to physicians on a per-patient-tested fee basis.  We believe that this approach allows physicians low financial risk access to our unique non-invasive cardiovascular disease screening products which should accelerate physician market acceptance,” added Guettler.

“The CVProfilor^® DO-2020 System introduction is focused on U.S. physicians’ offices and medical clinics.  To that end, we are pleased to announce that our Phase I launch resulted in 35 System placements as of June 30, 2001 .  As of June 30, 2001 , our cash and cash equivalents available to further support our product introduction amounted to approximately $3.9 million. Our Phase II launch, beginning July 1, 2001 , focuses on expanding geographic placements and market penetration via increases in field sales staffing.  As we proceed with the Phase II nationwide marketing stage of our plan, increased product utilization and third party reimbursement will be primary objectives and important to our continuing success,” Guettler stated.

About Hypertension Diagnostics

Hypertension Diagnostics, Inc. designs, develops, manufactures and markets proprietary cardiovascular profiling systems for clinical and research applications.  These systems are marketed to physicians, other health care professionals and researchers by a direct sales force and via distributors throughout the world.  In addition to providing blood pressure values, the systems non-invasively detect subtle changes in the compliance or elasticity of both large and small arteries which is a unique feature of HDI’s blood pressure waveform analysis technology.  The System includes a custom designed Arterial PulseWave™ Sensor to capture waveform data, as well as a printer which generates a CVProfile™ Report which can assist physicians in their clinical work.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2000 Annual Report on Form 10-KSB, as amended, under the caption “Risk Factors,” as well as others not now anticipated.

Hypertension Diagnostics, HDI/PulseWave™ and CVProfilor^® are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Contact: Greg H. Guettler, President